ID: ALA284536

Max Phase: Preclinical

Molecular Formula: C25H21N5O

Molecular Weight: 407.48

Molecule Type: Small molecule

Representations

Synonyms (1): ZD-8731
Synonyms from Alternative Forms(1):

Canonical SMILES:  CCc1cc(OCc2ccc(-c3ccccc3-c3nn[nH]n3)cc2)c2ccccc2n1

Standard InChI:  InChI=1S/C25H21N5O/c1-2-19-15-24(22-9-5-6-10-23(22)26-19)31-16-17-11-13-18(14-12-17)20-7-3-4-8-21(20)25-27-29-30-28-25/h3-15H,2,16H2,1H3,(H,27,28,29,30)

Standard InChI Key:  FSJCYXPMWQPVOS-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 407.48

Molecular Weight (Monoisotopic): 407.1746

AlogP: 5.22

#Rotatable Bonds: 6

Polar Surface Area: 76.58

Molecular Species: ACID

HBA: 5

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 6.34

CX Basic pKa: 5.86

CX LogP: 5.51

CX LogD: 4.88

Aromatic Rings: 5

Heavy Atoms: 31

QED Weighted: 0.42

Np Likeness Score: -0.82

References

1. Bradbury RH, Allott CP, Dennis M, Girdwood JA, Kenny PW, Major JS, Oldham AA, Ratcliffe AH, Rivett JE, Roberts DA..  (1993)  New nonpeptide angiotensin II receptor antagonists. 3. Synthesis, biological properties, and structure-activity relationships of 2-alkyl-4-(biphenylylmethoxy)pyridine derivatives.,  36  (9): [PMID:8487261] [10.1021/jm00061a016]

2. Bradbury R, Edwards M, Fisher E, Girdwood J, Major J, Oldham A, Patel M, Pearce R, Revill J, Ratcliffe A.  (1994)  New nonpeptide angiostensin II receptor antagonists. Synthesis, biological properties and structure-activity relationships of 3-substituted 2,6-dialkyl-4-(biphenyll)methylaminopyridine derivatives.,  4  (1): [10.1016/S0960-894X(01)81136-7]

3. Bradbury RH, Allott CP, Dennis M, Fisher E, Major JS, Masek BB, Oldham AA, Pearce RJ, Rankine N, Revill JM..  (1992)  New nonpeptide angiotensin II receptor antagonists. 2. Synthesis, biological properties, and structure-activity relationships of 2-alkyl-4-(biphenylylmethoxy)quinoline derivatives.,  35  (22): [PMID:1433210] [10.1021/jm00100a007]

4. Wexler RR, Greenlee WJ, Irvin JD, Goldberg MR, Prendergast K, Smith RD, Timmermans PB..  (1996)  Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.,  39  (3): [PMID:8576904] [10.1021/jm9504722]

5. Naik P, Murumkar P, Giridhar R, Yadav MR..  (2010)  Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.,  18  (24): [PMID:21071232] [10.1016/j.bmc.2010.10.043]

6. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

Source

Source(2):

• Scientific Literature
• AstraZeneca Deposited Data